ENTRADA THERAPEUTICS INC (TRDA) Stock News

USA - NASDAQ:TRDA - US29384C1080 - Common Stock

8.75 USD

-0.03 (-0.34%)

Last: 11/14/2025, 8:00:01 PM

8.6276 USD

-0.12 (-1.4%)

After Hours: 11/14/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TRDA Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

19 days ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics to Present at Upcoming Investor Conferences

19 days ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics to Present at Upcoming Investor Conferences

2 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

2 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

2 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: The Motley Fool

Entrada (TRDA) Q2 Revenue Drops 98%

3 months ago - By: Zacks Investment Research - Mentions: BRTX

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates

3 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

3 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

6 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

6 months ago - By: Entrada Therapeutics, Inc. - Mentions: BIIB

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

6 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

6 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

6 months ago - By: Zacks Investment Research - Mentions: BHST

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

6 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports First Quarter 2025 Financial Results

6 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports First Quarter 2025 Financial Results

7 months ago - By: Zacks Investment Research - Mentions: ETON

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release

7 months ago - By: Zacks Investment Research - Mentions: VRTX

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

8 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

8 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

9 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

9 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

9 months ago - By: Benzinga

FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy

9 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

9 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

10 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

10 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

10 months ago - By: Azenta - Mentions: AZTA

Azenta Announces the Election of Dipal Doshi to its Board of Directors